The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program
Open accessAbstract
BACKGROUND: Osteosarcoma, which is the most common primary bone tumor, occurs most frequently in adolescents, but there is a second incidence peak among individuals aged >60 years. Most osteosarcoma epidemiology studies have been embedded in large analyses of all bone tumors or focused on cases occurring in adolescence. Detailed descriptions of osteosarcoma incidence and survival with direct comparisons among patients of all ages and ethnicities are not available. METHODS: Frequency, incidence, and survival rates for 3482 patients with osteosarcoma from the National Cancer Institute's population‐based Surveillance, Epidemiology, and End Results (SEER) Program between 1973 and 2004 were investigated by age (ages 0‐24 years, 25‐59 years, and 60 to ≥85 years), race, sex, pathology subtype, stage, and anatomic site. RESULTS: There were large differences in incidence and survival rates by age. There was a high percentage of osteosarcoma with Paget disease and osteosarcoma as a second or later cancer among the elderly. There was a high percentage of osteosarcoma among patients with Paget disease and osteosarcoma as a second or later cancer among the elderly. Tumor site differences among age groups were noted. Survival rates varied by anatomic site and disease stage and did not improve significantly from 1984 to 2004. CONCLUSIONS: This comprehensive, population‐based description of osteosarcoma, identified important differences in incidence, survival, pathologic subtype, and anatomic site among age groups, and quantified the impact of osteosarcoma in patients with Paget disease or as a second cancer on incidence and mortality rates. These findings may have implications in understanding osteosarcoma biology and epidemiology. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Osteosarcoma is the most common primary malignant tumour of the bone.”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“higher rates of osteosarcoma have been observed in African American children and young adults in the USA than in white individuals 1 .”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Osteosarcoma incidence is bimodal, peaking at 18 and 60 years of age”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Osteosarcoma incidence has a bimodal age distribution with a primary peak in adolescents and young adults and a second, smaller peak in the seventh and eighth decade of life 1”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“In the USA, osteosarcoma accounts for <1% of all new cancer diagnoses with ~1,000 new cases diagnosed per year, half of these cases occurring in children and adolescents 1 .”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Some studies suggested that the histological subtype of osteosarcoma can influence the degree of necrosis, with chondroblastic and telangiectatic subtypes having less necrosis but those differences have not translated into improvement in survival 1,118 .”
From Osteosarcoma (2022) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,810
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
(1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,933
The international incidence of childhood cancer
Parkin, D. M., Stiller, C. A., Draper, G. J., & Bieber, C. A. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420408 · Cited by 1,022
Trends in childhood cancer incidence in the U.S. (1992–2004)
Linabery, A. M., & Ross, J. A. (2007) · Cancer · doi:10.1002/cncr.23169 · Cited by 644
Bleyer, A., O’Leary, M., Barr, R. D., & Ries, L. A. G. (2006) · Cited by 619
Osteosarcoma, Chondrosarcoma, and Ewing's Sarcoma
Damron, T. A., Ward, W. G., & Stewart, A. K. (2007) · Clinical Orthopaedics and Related Research · doi:10.1097/blo.0b013e318059b8c9 · Cited by 530
Osteogenic sarcoma. A study of six hundred cases.
Dahlin, D. C., & Coventry, M. B. (1967) · PubMed · Cited by 475
Bone Tumors: General Aspects and Data on 8,542 Cases
Spjut, H. J. (1987) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61914-4 · Cited by 455
Dahlin, D. C., & Coventry, M. B. (1967) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-196749010-00008 · Cited by 453
Flagged first, then by citations
2 of the 52 references couldn’t be matched to a known paper.
Research works printed but not linked: 12
- 10.1002/1097-0142(19950101)75:1 <203::AID-CNCR2820751308>3.0.CO;2-V · DOI
- Dorfman HA, 1997, Bone Tumors
- Murray RO, 1975, A Textbook of Radiology, 109
- Hanson MR, 1982, Epidemiology of Cancer in the Young
- 10.1002/1097-0142(19860715)58:2 <598::AID-CNCR2820581332>3.0.CO;2-C · DOI
- Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 2007, SEER Registries: Surveillance Research Program, National Cancer Institute
- Surveillance Research Program, 2007, National Cancer Institute SEER*Stat Software, version 6.3.6
- Day JC, 1996, Population Projections of the United States by Age, Sex, Race and Hispanic Origin, 1995 to 2050, US Bureau of the Census, Current Population Reports, P25‐1130
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 13 Regs Limited‐Use, November 2006 Submission (1992‐2004)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 9 Regs Limited‐Use, November 2006 Submission (1973‐2004)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 17 Regs Limited‐Use, November 2006 Submission (1973‐2004 varying)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Aegerter E, 1975, Orthopedic Disease
Cited by
Sorted by citations
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24320 · Cited by 791
Self-citationSmeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D., Gorlick, R., Janeway, K. A., Ingleby, F. C., Anninga, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.027 · Cited by 704
Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project
Stiller, C. A., Trama, A., Serraino, D., Rossi, S., Navarro, C., Chirlaque, M. D., & Casali, P. G. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.09.011 · Cited by 693
Current and future therapeutic approaches for osteosarcoma
Harrison, D. J., Geller, D. S., Gill, J. B., Lewis, V. O., & Gorlick, R. G. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1413939 · Cited by 691
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Lindsey, B. A., Markel, J., & Kleinerman, E. S. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 490
Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419260111 · Cited by 481
Osteosarcoma, Chondrosarcoma, and Chordoma
Whelan, J., & Davis, L. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1743 · Cited by 477
Osteosarcoma: a review of diagnosis, management, and treatment strategies.
Geller, D. S., & Gorlick, R. G. (2010) · PubMed · Cited by 475
Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy
Gianferante, D. M., Mirabello, L. J., & Savage, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.16 · Cited by 477
Self-citationDescriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project
Stiller, C. A., Trama, A., Brewster, D., Verne, J., Bouchardy, C., Navarro, C., Chirlaque, M. D., Marcos‐Gragera, R., Visser, O. J., Serraino, D., et al. (2014) · Cancer Epidemiology · doi:10.1016/j.canep.2014.09.009 · Cited by 463
Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
Anninga, J. K., Gelderblom, H., Fiocco, M., Kroep, J. R., Taminiau, A. H. M., Hogendoorn, P. C. W., & Egeler, R. M. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.030 · Cited by 456
Bielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422
Review of Osteosarcoma and Current Management
Durfee, R. A., Mohammed, M., & Luu, H. H. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0046-y · Cited by 409
Dog models of naturally occurring cancer
Rowell, J., McCarthy, D. O., & Alvarez, C. E. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.02.004 · Cited by 413
Moore, D. D., & Luu, H. H. (2014) · Cancer treatment and research · doi:10.1007/978-3-319-07323-1_4 · Cited by 350
Osteosarcoma: a review of current and future therapeutic approaches
Zhao, X. B., Wu, Q., Gong, X., Liu, J., & Ma, Y. (2021) · BioMedical Engineering OnLine · doi:10.1186/s12938-021-00860-0 · Cited by 341
Duchman, K. R., Gao, Y., & Miller, B. J. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.05.001 · Cited by 303
Using Epidemiology and Genomics to Understand Osteosarcoma Etiology
Savage, S. A., & Mirabello, L. J. (2011) · Sarcoma · doi:10.1155/2011/548151 · Cited by 309
Self-citationCommon Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., Rose, P. S., Folpe, A. L., & Laack, N. N. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.01.015 · Cited by 298
Simpson, S., Dunning, M., de Brot, S., Grau‐Roma, L., Mongan, N. P., & Rutland, C. S. (2017) · Acta veterinaria Scandinavica · doi:10.1186/s13028-017-0341-9 · Cited by 304
Bone Microenvironment and Osteosarcoma Metastasis
Yang, C., Tian, Y. E., Zhao, F., Chen, Z., Su, P., Li, Y., & Qian, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21196985 · Cited by 298
Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 300
Upconversion NIR-II fluorophores for mitochondria-targeted cancer imaging and photothermal therapy
Zhou, H., Zeng, X., Li, A., Zhou, W., Tang, L., Hu, W., Fan, Q., Meng, X., Deng, H., Duan, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19945-w · Cited by 290
Osteosarcoma: A Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017
Cole, S., Gianferante, D. M., Zhu, B., & Mirabello, L. (2022) · Cancer · doi:10.1002/cncr.34163 · Cited by 277
Self-citationNew targets and approaches in osteosarcoma
Gill, J. B., Ahluwalia, M., Geller, D., & Gorlick, R. G. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.003 · Cited by 274
Andrews, E. B., Gilsenan, A., Midkiff, K. D., Sherrill, B. H., Wu, Y., Mann, B. H., & Masica, D. N. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1768 · Cited by 272
Fujiwara, T., Yakoub, M. A., Chandler, A., Christ, A. B., Yang, G., Ouerfelli, O., Rajasekhar, V. K., Yoshida, A., Kondo, H., Hata, T., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0591 · Cited by 279
Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267
Future directions in the treatment of osteosarcoma
Bishop, M. W., Janeway, K. A., & Gorlick, R. G. (2015) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000298 · Cited by 266
Incidence and survival of malignant bone sarcomas in England 1979–2007
Whelan, J., McTiernan, A., Cooper, N. S., Wong, Y. K., Francis, M., Vernon, S., & Strauss, S. J. (2011) · International Journal of Cancer · doi:10.1002/ijc.26426 · Cited by 261
Osteosarcoma: A comprehensive review of management and treatment strategies
Jafari, F., Javdansirat, S., Sanaie, S., Naseri, A., Shamekh, A., Rostamzadeh, D., & Dolati, S. (2020) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2020.151654 · Cited by 253
Immuno-genomic landscape of osteosarcoma
Wu, C.-C., Beird, H. C., Andrew Livingston, J., Advani, S., Mitra, A., Cao, S., Reuben, A., Ingram, D., Wang, W.-L., Ju, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14646-w · Cited by 251
Canine Osteosarcoma: A Naturally Occurring Disease to Inform Pediatric Oncology
Fenger, J. M., London, C. A., & Kisseberth, W. C. (2014) · ILAR Journal · doi:10.1093/ilar/ilu009 · Cited by 248
Lauvrak, S. U., Munthe, E., Kresse, S. H., Stratford, E. W., Namløs, H. M., Meza‐Zepeda, L. A., & Myklebost, O. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.549 · Cited by 252
Mirabello, L., Zhu, B., Koster, R., Karlins, E., Dean, M., Yeager, M., Gianferante, M., Spector, L. G., Morton, L. M., Karyadi, D., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0197 · Cited by 243
Self-citationEpidemiology and Risk Factors of Osteosarcoma
Sadykova, L. R., Ntekim, A., Muyangwa-Semenova, M., Rutland, C. S., Jeyapalan, J. N., Blatt, N. L., & Rizvanov, A. A. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1768401 · Cited by 246
Huang, K., Chen, Y., Zhang, R., Wu, Y., Ma, Y., Fang, X., & Shen, S. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0166-5 · Cited by 236
Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?
Mutsaers, A. J., & Walkley, C. R. (2014) · Bone · doi:10.1016/j.bone.2014.02.003 · Cited by 233
Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline
Ralston, S. H., Corral-Gudino, L., Cooper, C. C., Francis, R. M., Fraser, W. D., Gennari, L., Guañabens, N., Javaid, M. K., Layfield, R., O’Neill, T. W., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3657 · Cited by 235
Belayneh, R., Fourman, M. S., Bhogal, S. S., & Weiss, K. R. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01053-7 · Cited by 230
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226
Zhao, G., Cai, C., Yang, T.-T., Qiu, X., Liao, B., Li, W., Ji, Z., Zhao, J., Zhao, H., Guo, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053906 · Cited by 227
Future Directions in the Treatment of Osteosarcoma
Smrke, A., Anderson, P. M., Gulia, A., Gennatas, S., Huang, P. H., & Jones, R. L. (2021) · Cells · doi:10.3390/cells10010172 · Cited by 230
Pediatric osteosarcoma: An updated review
Taran, R., Taran, S., & Malipatil, N. (2017) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/0971-5851.203513 · Cited by 221
Eaton, B. R., Schwarz, R., Vatner, R. E., Yeh, B. K., Claude, L., Indelicato, D. J., & Laack, N. N. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28352 · Cited by 216
Jiang, N., Wang, X., Xie, X., Liao, Y., Liu, N., Liu, J., Miao, N., Shen, J., & Peng, T. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.009 · Cited by 212
Whelan, J. S., Jinks, R. C., McTiernan, A., Sydes, M. R., Hook, J., Trani, L., Uscinska, B., Bramwell, V. H. C., Lewis, I. J., Nooij, M. A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr491 · Cited by 207
Sheng, G., Gao, Y., Yong, Y., & Wu, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.780264 · Cited by 215
Genome-wide association study identifies two susceptibility loci for osteosarcoma
Savage, S. A., Mirabello, L. J., Wang, Z., Gastier, J. M., Gorlick, R. G., Khanna, C., Flanagan, A. M., Tirabosco, R., Andrulis, I. L., Wunder, J. S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2645 · Cited by 200
Self-citationProgrammed Cell Death Ligand 1 Expression in Osteosarcoma
Shen, J. K., Cote, G. M., Choy, E., Yang, P., Harmon, D. C., Schwab, J. H., Nielsen, G. P., Chebib, I. A., Ferrone, S., Wang, X., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0224 · Cited by 200
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
PosthumaDeBoer, J., Witlox, A. M. A., Kaspers, G. J. L., & van Royen, B. J. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9384-x · Cited by 194
Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy
Huang, X., Wu, W., Jing, D., Yang, L., Guo, H., Wang, L., Zhang, W., Pu, F., & Shao, Z. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.026 · Cited by 188
Imaging Characteristics of Primary Osteosarcoma: Nonconventional Subtypes
Yarmish, G. M., Klein, M. J., Landa, J., Lefkowitz, R. A., & Hwang, S. (2010) · Radiographics · doi:10.1148/rg.306105524 · Cited by 191
Xin, M., Qiao, Z., Li, J., Liu, J., Song, S., Zhao, X., Miao, P., Tang, T., Wang, L., Liu, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10020 · Cited by 179
Risk Factors for Metastatic Disease at Presentation with Osteosarcoma
Miller, B. J., Cram, P. M., Lynch, C. F., & Buckwalter, J. A. (2013) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.l.01189 · Cited by 177
EF24 induces ferroptosis in osteosarcoma cells through HMOX1
Lin, H., Chen, X., Zhang, C., Yang, T., Deng, Z., Song, Y., Huang, L. J., Li, F., Li, Q., Lin, S., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111202 · Cited by 176
Landry, J. P., Schertz, K. L., Chiang, Y., Bhalla, A. D., Yi, M., Keung, E. Z.-Y., Scally, C. P., Feig, B. W., Hunt, K. K., Roland, C. L., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.0945 · Cited by 171
Gorlick, R., & Khanna, C. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.77 · Cited by 157
Germline TP53 Variants and Susceptibility to Osteosarcoma
Mirabello, L., Yeager, M., Mai, P. L., Gastier-Foster, J. M., Gorlick, R., Khanna, C., Patiño-Garcia, A., Sierrasesúmaga, L., Lecanda, F., Andrulis, I. L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv101 · Cited by 155
Self-citationInactive Wnt/β‐catenin pathway in conventional high‐grade osteosarcoma
Cai, Y., Mohseny, A. B., Karperien, M., Hogendoorn, P. C. W., Zhou, G., & Cleton-Jansen, A. (2009) · The Journal of Pathology · doi:10.1002/path.2628 · Cited by 158
Bone cancer incidence by morphological subtype: a global assessment
Valery, P. C., Laversanne, M., & Bray, F. (2015) · Cancer Causes & Control · doi:10.1007/s10552-015-0607-3 · Cited by 154
Advances in the management of osteosarcoma
Bielack, S., Hecker‐Nolting, S., Blattmann, C., & Kager, L. (2016) · F1000Research · doi:10.12688/f1000research.9465.1 · Cited by 152
LncRNA SNHG3/miRNA-151a-3p/RAB22A axis regulates invasion and migration of osteosarcoma
Zheng, S., Jiang, F., Ge, D., Tang, J. X., Chen, H., Yang, J., Yao, Y., Yan, J., Qiu, J., Yin, Z., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108695 · Cited by 149
MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects
Miao, J., Wu, S., Peng, Z., Tania, M., & Zhang, C. (2013) · Tumor Biology · doi:10.1007/s13277-013-0940-7 · Cited by 146
Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets
Li, Z., Dou, P., Liu, T., & He, S. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479205 · Cited by 143
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
Harris, M. A., & Hawkins, C. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073817 · Cited by 148
Huang, X., Zhao, J., Bai, J., Shen, H. M., Zhang, B., Deng, L., Sun, C., Liu, Y., Zhang, J., & Zheng, J. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100230 · Cited by 142
Safety of osteoanabolic therapy: A decade of experience
Capriani, C., Irani, D., & Bilezikian, J. P. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1800 · Cited by 141
TP53 in bone and soft tissue sarcomas
Thoenen, E. A., Curl, A., & Iwakuma, T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.010 · Cited by 140
de Andrade, K. C., Khincha, P. P., Hatton, J. N., Frone, M. N., Wegman-Ostrosky, T., Mai, P. L., Best, A. F., & Savage, S. A. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00580-5 · Cited by 145
Self-citationStatistics of bone sarcoma in Japan: Report from the Bone and Soft Tissue Tumor Registry in Japan
Ogura, K., Higashi, T., & Kawai, A. (2016) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2016.10.006 · Cited by 136
Recent advances of drug delivery nanocarriers in osteosarcoma treatment
Wang, S., Hu, H.-Z., Qing, X.-C., Zhang, Z., & Shao, Z.-W. (2019) · Journal of Cancer · doi:10.7150/jca.36588 · Cited by 137
Miao, W., Chen, J., Jia, L., Ma, J., & Song, D. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.06.128 · Cited by 132
Xie, C., Cao, Y., Huang, Y., Qun-wei, S., Guo, J., Fan, Z.-W., Li, J.-G., Chen, B., & Wu, B. (2016) · Tumor Biology · doi:10.1007/s13277-016-5391-5 · Cited by 132
Review of the Molecular Pathogenesis of Osteosarcoma
He, J., Hao, Y. X., Wang, X., Yang, X.-J., Shao, J., Guo, F.-J., & Feng, J. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.15.5967 · Cited by 130
Li, Z., Zhao, L., & Wang, Q. (2016) · PubMed Central · Cited by 126
Liu, X., Hu, A., Zhao, J., & Chen, F. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26050 · Cited by 126
EMT transcription factors: implication in osteosarcoma
Yang, G., Yuan, J., & Li, K. (2013) · Medical Oncology · doi:10.1007/s12032-013-0697-2 · Cited by 125
Wang, Y., Yang, T., Zhang, Z., Lu, M., Zhao, W. G., Zeng, X., & Zhang, W. (2017) · Cancer Science · doi:10.1111/cas.13201 · Cited by 125
Yuan, Y., Yan, G., He, M., Lei, H., Li, L., Wang, Y., He, X., Li, G., Wang, Q., Gao, Y., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03315-x · Cited by 125
Sun, X., Yang, L., Geng, X., Wang, R., & Zhang, Z. (2015) · PubMed Central · Cited by 125
Ligon, J. A., Choi, W., Cojocaru, G., Fu, W., Hsiue, E. H.-C., Oke, T. F., Siegel, N., Fong, M. H., Ladle, B., Pratilas, C. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001772 · Cited by 124
Review of mifamurtide in the treatment of patients with osteosarcoma
Kager, L., Pötschger, U., & Bielack (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5688 · Cited by 124
Baker, E. K., Taylor, S., Gupte, A., Sharp, P. P., Walia, M., Walsh, N. C., Zannettino, A. C. W., Chalk, A. M., Burns, C. J., & Walkley, C. R. (2015) · Scientific Reports · doi:10.1038/srep10120 · Cited by 123
Wang, T., Gong, X., Jiang, R., Li, H., Du, W., & Kuang, G. (2016) · PubMed Central · Cited by 122
Wnt signaling and Loxl2 promote aggressive osteosarcoma
Matsuoka, K., Bakiri, L., Wolff, L. I., Linder, M., Mikels, A. J., Patiño‐García, A., Lecanda, F., Hartmann, C., Sibilia, M. C., & Wagner, E. F. (2020) · Cell Research · doi:10.1038/s41422-020-0370-1 · Cited by 121
Eaton, B. R., Claude, L., Indelicato, D. J., Vatner, R. E., Yeh, B. K., Schwarz, R., & Laack, N. N. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.28355 · Cited by 120
Survival Prediction in High-grade Osteosarcoma Using Radiomics of Diagnostic Computed Tomography
Wu, Y., Xu, L., Yang, P., Lin, N., Huang, X., Pan, W., Li, H., Lin, P., Li, B., Bunpetch, V., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.07.006 · Cited by 119
Fujiwara, T., Uotani, K., Yoshida, A., Morita, T., Nezu, Y., Kobayashi, E., Yoshida, A., Uehara, T., Omori, T., Sugiu, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16498 · Cited by 118
Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies
Zahnreich, S., & Schmidberger, H. (2021) · Cancers · doi:10.3390/cancers13112607 · Cited by 132
Height at diagnosis and birth-weight as risk factors for osteosarcoma
Mirabello, L., Pfeiffer, R., Murphy, G., Daw, N. C., Patiño-Garcia, A., Troisi, R. J., Hoover, R. N., Douglass, C., Schüz, J., Craft, A. W., et al. (2011) · Cancer Causes & Control · doi:10.1007/s10552-011-9763-2 · Cited by 116
Self-citationKelly, A. D., Haibe‐Kains, B., Janeway, K. A., Hill, K. E., Howe, E., Goldsmith, J. D., Kurek, K. C., Pérez‐Atayde, A. R., Francoeur, N. J., Fan, J., et al. (2013) · Genome Medicine · doi:10.1186/gm406 · Cited by 115
Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison
Marko, T. A., Diessner, B. J., & Spector, L. G. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.25963 · Cited by 115
Aspirin Suppresses the Growth and Metastasis of Osteosarcoma through the NF-κB Pathway
Liao, D., Zhong, L., Duan, T., Zhang, R.-H., Wang, X., Wang, G., Hu, K., Lv, X., & Kang, T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0198 · Cited by 114
Ho, X. D., Phung, P., Le, V. Q., Nguyễn, V. H., Reimann, E., Prans, E., Kõks, G., Maasalu, K., Le, N. T. N., Trinh, L. H., et al. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217736512 · Cited by 120
Sun, X., & Wei, G. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100281 · Cited by 114
Lin, C. H., Ji, T., Chen, C., & Hoang, B. H. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_2 · Cited by 114
Scott, M. C., Temiz, N. A., Sarver, A. E., LaRue, R. S., Rathe, S. K., Varshney, J., Wolf, N. K., Moriarity, B. S., O’Brien, T. D., Spector, L. G., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0576 · Cited by 117
Metadata
- Authors
- Mirabello, L., Troisi, R. J., & Savage, S. A.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Savage, Sharon A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-02-05
- Volume
- 115
- Issue
- 7
- Pages
- 1531-1543
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC2813207
- OpenAlex
- W1988325237
- Cited by
- 2,199
- References
- 52
- Citations by year
- 2026: 114 · 2025: 138 · 2024: 166 · 2023: 167 · 2022: 161 · 2021: 194 · 2020: 201 · 2019: 162 · 2018: 172 · 2017: 142 · 2016: 151 · 2015: 129 · 2014: 106 · 2013: 72 · 2012: 52
- FWCI
- 33.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01CP010142)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- osteosarcoma, incidence, survival rate, age differences, Paget disease, secondary malignancies, elderly patients, disease stage, SEER, bone tumors, mortality trends
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Bone Neoplasms, Child, Child, Preschool, Ethnicity, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Osteosarcoma, Sex Factors, Survival Rate, SEER Program
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
